|
1
|
Brøchner CB, Johansen JS, Larsen LA, Bak
M, Mikkelsen HB, Byskov AG, Andersen CY and Møllgård K: YKL-40 is
differentially expressed in human embryonic stem cells and in cell
progeny of the three germ layers. J Histochem Cytochem. 60:188–204.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Francescone RA, Scully S, Faibish M,
Taylor SL, Oh D, Moral L, Yan W, Bentley B and Shao R: Role of
YKL-40 in the angiogenesis, radioresistance, and progression of
glioblastoma. J Biol Chem. 286:15332–15343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee CG, Hartl D, Lee GR, Koller B,
Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, et
al: Role of breast regression protein 39 (BRP-39)/chitinase
3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J
Exp Med. 206:1149–1166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fan JT, Si XH, Liao Y and Shen P: The
diagnostic and prognostic value of serum YKL-40 in endometrial
cancer. Arch Gynecol Obstet. 287:111–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li LL, Fan JT, Li DH and Liu Y: Effects of
a small interfering RNA targeting YKL-40 gene on the proliferation
and invasion of endometrial cancer HEC-1A cells. Int J Gynecol
Cancer. 26:1190–1195. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chiang YC, Lin HW, Chang CF, Chang MC, Fu
CF, Chen TC, Hsieh SF, Chen CA and Cheng WF: Overexpression of
CHI3L1 is associated with chemoresistance and poor outcome of
epithelial ovarian carcinoma. Oncotarget. 6:39740–39755. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lax SF: Pathology of endometrial
carcinoma. Adv Exp Med Biol. 943:75–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dossus L, Allen N, Kaaks R, Bakken K, Lund
E, Tjonneland A, Olsen A, Overvad K, Clavel-Chapelon F, Fournier A,
et al: Reproductive risk factors and endometrial cancer: The
European prospective investigation into cancer and nutrition. Int J
Cancer. 127:442–451. 2010.PubMed/NCBI
|
|
9
|
Zhu Y, Shen J, Gao L and Feng Y: Estrogen
promotes fat mass and obesity-associated protein nuclear
localization and enhances endometrial cancer cell proliferation via
the mTOR signaling pathway. Oncol Rep. 35:2391–2397. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roslind A and Johansen JS: YKL-40: A novel
marker shared by chronic inflammation and oncogenic transformation.
Methods Mol Biol. 511:159–184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steponaitis G, Skiriutė D, Kazlauskas A,
Golubickaitė I, Stakaitis R, Tamašauskas A and Vaitkienė P: High
CHI3L1 expression is associated with glioma patient survival. Diagn
Pathol. 11:422016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thongsom S, Chaocharoen W, Silsirivanit A,
Wongkham S, Sripa B, Choe H, Suginta W and Talabnin C:
YKL-40/chitinase-3-like protein 1 is associated with poor prognosis
and promotes cell growth and migration of cholangiocarcinoma.
Tumour Biol. 37:9451–9463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Johansen JS, Christensen IJ, Jørgensen LN,
Olsen J, Rahr HB, Nielsen KT, Laurberg S, Brünner N and Nielsen HJ:
Serum YKL-40 in risk assessment for colorectal cancer: A
prospective study of 4,496 subjects at risk of colorectal cancer.
Cancer Epidemiol Biomarkers Prev. 24:621–626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang XW, Cai CL, Xu JM, Jin H and Xu ZY:
Increased expression of chitinase 3-like 1 is a prognosis marker
for non-small cell lung cancer correlated with tumor angiogenesis.
Tumour Biol. 36:901–907. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vom Dorp F, Tschirdewahn S, Niedworok C,
Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF,
Nyirady P, et al: Circulating and tissue expression levels of
YKL-40 in renal cell cancer. J Urol. 195:1120–1125. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thorn AP, Daugaard S, Christensen LH,
Christensen IJ and Petersen MM: YKL-40 protein in osteosarcoma
tumor tissue. APMIS. 124:453–461. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lai T, Chen M, Deng Z, L Y, Wu D, Li D and
Wu B: YKL-40 is correlated with FEV1 and the asthma control test
(ACT) in asthmatic patients: Influence of treatment. BMC Pulm Med.
15:12015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gudmundsdottir S, Lieder R, Sigurjonsson
OE and Petersen PH: Chitosan leads to downregulation of YKL-40 and
inflammasome activation in human macrophages. J Biomed Mater Res A.
103:2778–2785. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zou L, He X and Zhang JW: The efficacy of
YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Braz
J Med Biol Res. 43:1232–1238. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fan JT, Li MJ, Shen P, Xu H, Li DH and Yan
HQ: Serum and tissue level of YKL-40 in endometrial cancer. Eur J
Gynaecol Oncol. 35:304–308. 2014.PubMed/NCBI
|
|
21
|
Kemik P, Saatli B, Yıldırım N, Kemik VD,
Deveci B, Terek MC, Koçtürk S, Koyuncuoğlu M and Saygılı U:
Diagnostic and prognostic values of preoperative serum levels of
YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol.
140:64–69. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang W, Kawanishi M, Miyake K, Kagawa M,
Kawai N, Murao K, Nishiyama A, Fei Z, Zhang X and Tamiya T:
Association between YKL-40 and adult primary astrocytoma. Cancer.
116:2688–2697. 2010.PubMed/NCBI
|
|
23
|
Kawada M, Seno H, Kanda K, Nakanishi Y,
Akitake R, Komekado H, Kawada K, Sakai Y, Mizoguchi E and Chiba T:
Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis
in colorectal cancer. Oncogene. 31:3111–3123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen CC, Pekow J, Llado V, Kanneganti M,
Lau CW, Mizoguchi A, Mino-Kenudson M, Bissonnette M and Mizoguchi
E: Chitinase 3-like-1 expression in colonic epithelial cells as a
potentially novel marker for colitis-associated neoplasia. Am J
Pathol. 179:1494–1503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akiyama Y, Ashizawa T, Komiyama M, Miyata
H, Oshita C, Omiya M, Iizuka A, Kume A, Sugino T, Hayashi N, et al:
YKL-40 downregulation is a key factor to overcome temozolomide
resistance in a glioblastoma cell line. Oncol Rep. 32:159–166.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van Linde ME, van der Mijn JC, Pham TV,
Knol JC, Wedekind LE, Hovinga KE, Aliaga ES, Buter J, Jimenez CR,
Reijneveld JC and Verheul HM: Evaluation of potential circulating
biomarkers for prediction of response to chemoradiation in patients
with glioblastoma. J Neurooncol. 129:221–230. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boisen MK, Madsen CV, Dehlendorff C,
Jakobsen A, Johansen JS and Steffensen KD: The prognostic value of
plasma YKL-40 in patients with chemotherapy-resistant ovarian
cancer treated with bevacizumab. Int J Gynecol Cancer.
26:1390–1398. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ku BM, Lee YK, Ryu J, Jeong JY, Choi J,
Eun KM, Shin HY, Kim DG, Hwang EM, Yoo JC, et al: CHI3L1 (YKL-40)
is expressed in human gliomas and regulates the invasion, growth
and survival of glioma cells. Int J Cancer. 128:1316–1326. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jefri M, Huang YN, Huang WC, Tai CS and
Chen WL: YKL-40 regulated epithelial-mesenchymal transition and
migration/invasion enhancement in non-small cell lung cancer. BMC
Cancer. 15:5902015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mylin AK, Abildgaard N, Johansen JS,
Heickendorff L, Kreiner S, Waage A, Turesson I and Gimsing P:
Nordic Myeloma Study Group; Serum YKL-40: A new independent
prognostic marker for skeletal complications in patients with
multiple myeloma. Leuk Lymphoma. 56:2650–2659. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jeet V, Tevz G, Lehman M, Hollier B and
Nelson C: Elevated YKL40 is associated with advanced prostate
cancer (PCa) and positively regulates invasion and migration of PCa
cells. Endocr Relat Cancer. 21:723–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
